Search results
Showing 16 to 30 of 132 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
In development Reference number: GID-TA11531 Expected publication date: TBC
Percutaneous Laser Ablation (PLA) for benign thyroid nodules
Topic prioritisation
Transoral Endoscopic Thyroid/Parathyroid Vestibular Approach
Topic prioritisation
Transoral endoscopic thyroid surgery via a vestibular approach
Topic prioritisation
This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.
Diabetes: thyroid disease screening (children T1DM) (IND312)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04
Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (HTG416)
Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults. This involves using heat energy to destroy tissue in the nodules.
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules (HTG646)
Evidence-based recommendations on percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. This involves using microwaves from a wire inserted into the nodule to heat and destroy it (ablation).
View recommendations for HTG646Show all sections
Intraoperative nerve monitoring during thyroid surgery (HTG164)
Evidence-based recommendations on intraoperative nerve monitoring during thyroid surgery. This involves placing electrodes near the vocal cords to alert the surgeon when a surgical instrument comes close to either of the laryngeal nerves.
View recommendations for HTG164Show all sections
Sections for HTG164
High-intensity focused ultrasound for symptomatic benign thyroid nodules (HTG504)
Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults. This involves using heat made by high-frequency sound waves to destroy the nodule.
View recommendations for HTG504Show all sections